Guangzhou Baiyunshan Secures Marketing Authorization for Compound Acetaminophen Granules

MT Newswires Live08-19

Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) unit Guangxi Baiyunshan Yingkang Pharmaceutical has obtained marketing authorization for compound acetaminophen granules from China's National Medical Products Administration, a Friday disclosure on the Shanghai Stock Exchange said.

The company successfully transferred the marketing authorization for the drug from its subsidiary to itself. Compound acetaminophen granules are indicated for the relief of fever and headache associated with the common cold and influenza.

The drug is used to relieve fever and headache caused by common cold and influenza, the disclosure added.

Price (HKD): $29.85, Change: $-0.050, Percent Change: -0.17%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2460232701?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-19 15:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2460232701","market":"sg","top_or_hot":-1,"title":"Guangzhou Baiyunshan Secures Marketing Authorization for Compound Acetaminophen Granules","media":"MT Newswires Live","content":"<html><body><p> Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) unit Guangxi Baiyunshan Yingkang Pharmaceutical has obtained marketing authorization for compound acetaminophen granules from China's National Medical Products Administration, a Friday disclosure on the Shanghai Stock Exchange said.</p><p>The company successfully transferred the marketing authorization for the drug from its subsidiary to itself. Compound acetaminophen granules are indicated for the relief of fever and headache associated with the common cold and influenza.</p><p>The drug is used to relieve fever and headache caused by common cold and influenza, the disclosure added.</p><p>Price (HKD): $29.85, Change: $-0.050, Percent Change: -0.17%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guangzhou Baiyunshan Secures Marketing Authorization for Compound Acetaminophen Granules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuangzhou Baiyunshan Secures Marketing Authorization for Compound Acetaminophen Granules\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-19 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) unit Guangxi Baiyunshan Yingkang Pharmaceutical has obtained marketing authorization for compound acetaminophen granules from China's ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2460232701","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2460232701","pubTimestamp":1724054292,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guangzhou Baiyunshan Pharmaceutical  unit Guangxi Baiyunshan Yingkang Pharmaceutical has obtained marketing authorization for compound acetaminophen granules from China's National Medical Products Administration, a Friday disclosure on the Shanghai Stock Exchange said.The company successfully transferred the marketing authorization for the drug from its subsidiary to itself. Compound acetaminophen granules are indicated for the relief of fever and headache associated with the common cold and influenza.The drug is used to relieve fever and headache caused by common cold and influenza, the disclosure added.Price : $29.85, Change: $-0.050, Percent Change: -0.17%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0183":"MSCI概念","BK0012":"证金概念","BK0196":"行业龙头","BK0097":"医药电商","BK4023":"应用软件","BK0096":"民营医院","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","BK1606":"中医药概念","BK0028":"国家队","BK1197":"保健护理产品经销商","BK4588":"碎股","BK4526":"热门中概股","BK0188":"融资融券","BK0070":"员工持股","BK0239":"医药制造","00874":"白云山","HKD":"尚乘数科","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","BK0175":"白马股"},"translate_title":"广州白云山获得复方对乙酰氨基酚颗粒上市许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":0.9,"HKD":1,"00874":0.9},"content_text":"Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) unit Guangxi Baiyunshan Yingkang Pharmaceutical has obtained marketing authorization for compound acetaminophen granules from China's National Medical Products Administration, a Friday disclosure on the Shanghai Stock Exchange said.The company successfully transferred the marketing authorization for the drug from its subsidiary to itself. Compound acetaminophen granules are indicated for the relief of fever and headache associated with the common cold and influenza.The drug is used to relieve fever and headache caused by common cold and influenza, the disclosure added.Price (HKD): $29.85, Change: $-0.050, Percent Change: -0.17%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460232701"}